Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
22 09 2022
Historique:
pubmed: 8 9 2022
medline: 24 9 2022
entrez: 7 9 2022
Statut: ppublish

Résumé

An imidazolone → triazolone replacement addressed the limited passive permeability of a series of protein arginine methyl transferase 5 (PRMT5) inhibitors. This increase in passive permeability was unexpected given the increase in the hydrogen bond acceptor (HBA) count and topological polar surface area (TPSA), two descriptors that are typically inversely correlated with permeability. Quantum mechanics (QM) calculations revealed that this unusual effect was due to an electronically driven disconnect between TPSA and 3D-PSA, which manifests in a reduction in overall HBA strength as indicated by the HBA moment descriptor from COSMO-RS (conductor-like screening model for real solvation). HBA moment was subsequently deployed as a design parameter leading to the discovery of inhibitors with not only improved passive permeability but also reduced P-glycoprotein (P-gp) transport. Our case study suggests that hidden polarity as quantified by TPSA-3DPSA can be rationally designed through QM calculations.

Identifiants

pubmed: 36069672
doi: 10.1021/acs.jmedchem.2c01068
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B, Member 1 0
Arginine 94ZLA3W45F
Transferases EC 2.-
PRMT5 protein, human EC 2.1.1.319
Protein-Arginine N-Methyltransferases EC 2.1.1.319
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12386-12402

Auteurs

Upendra Argikar (U)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Markus Blatter (M)

Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Dallas Bednarczyk (D)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Zhuoliang Chen (Z)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Young Shin Cho (YS)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Michaël Doré (M)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Jennifer L Dumouchel (JL)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Samuel Ho (S)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Klemens Hoegenauer (K)

Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Toshio Kawanami (T)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Simon Mathieu (S)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Erik Meredith (E)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Henrik Möbitz (H)

Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Stephen K Murphy (SK)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Saravanan Parthasarathy (S)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Carole Pissot Soldermann (CP)

Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Jobette Santos (J)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Serena Silver (S)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Suzanne Skolnik (S)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Aleksandar Stojanovic (A)

Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH